Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harmine in Healthy Subjects
NCT05526430Phase 1Completed
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of harmine in diabetes mellitus (DM). Primary endpoints: Dose Limiting Toxicity at 24 hours and Maximum Tolerated Dose at 24 hours. Started Sep 2022; status: completed.
02
Drugs
harmine
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05526430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526430.